LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology companydevoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to provide an update on current early-stage research programs. The day will include
Management presentations will begin at 9:00 a.m. Eastern Time on Tuesday, June 26, 2018, at the offices of Dechert, LLP in New York City.
A live webcast of the presentation and slide deck will be available via the Company's Investor Relations website at http://ir.aldeyra.com. Following the live webcast, an archived version will be available on the website until June 25, 2019.
About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: +1 781-761-4904 ext. 218 email@example.com
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.firstname.lastname@example.org
Media Contact:Cammy Duong MacDougall Biomedical Communications email@example.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-2018-research-day-300669225.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!
Paralysis is a condition where there is a loss of muscle function as well as sensory loss, which ...
Swine flu, a type of influenza caused by a new strain of the H1N1 Type A influenza virus has ...
Body wraps is an all natural remedy to slenderizing & contouring your body that not just hydrate ...View All